Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease by Yuan-Yuan Xu, Xu Wang, Yu-Qing She, Jie Liu, Qing Zhang

“…This study aimed to systematically evaluate the efficacy of liraglutide in treating type 2 diabetes mellitus (T2DM) complicated with non-alcoholic fatty liver disease (NAFLD) by comparing liraglutide with placebo or other drugs (mainly insulin). The PubMed, Web of Science, and National Library of Medicine databases were systematically searched from their inception until December 1, 2023. …”
Get full text

The Clinical and Steroid-Free Remission of Fecal Microbiota Transplantation to Patients with Ulcerative Colitis: A Meta-Analysis by Wai Ching Lam, Chen Zhao, Wen Juan Ma, Liang Yao

“…We found that FMT might be more effective than placebo on clinical remission (OR, 3.85 [2.21, 6.7]; P<0.001; I2=0%) and clinical response (OR, 2.75 [1.33, 5.67]; P=0.006; I2=49%), but no statistical difference on steroid-free remission (OR, 2.08 [0.41, 10.5]; P=0.37; I2=69%) and serious adverse events (OR, 2.0 [0.17, 22.97]; P=0.44; I2=0%). …”
Get full text

Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life by Andrew Blauvelt, Mark Boguniewicz, Patrick M. Brunner, Paula C. Luna, Pinaki Biswas, Marco DiBonaventura, Saleem A. Farooqui, Ricardo Rojo, Michael C. Cameron

“…Background Abrocitinib, a once-daily, oral Janus kinase 1 selective inhibitor, was shown to be an effective treatment for moderate-to-severe atopic dermatitis in phase 2 b/3 monotherapy trials.Methods These analyses included data for Investigator’s Global Assessment responder (clear [0] or almost clear [1] with ≥2-grade improvement) and nonresponder patients with moderate-to-severe atopic dermatitis who received abrocitinib (200 mg or 100 mg) or placebo in three abrocitinib monotherapy trials (phase 2 b, NCT02780167; two phase 3, NCT03349060/JADE MONO-1 and NCT03575871/JADE MONO-2). …”
Get full text

Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus by Feng-fei Li, Gu Gao, Qian Li, Hong-hong Zhu, Xiao-fei Su, Jin-dan Wu, Lei Ye, Jian-hua Ma

“…This was a randomized, double-blind, placebo-controlled, phase 3 trial. A total of 28 patients with newly diagnosed T2DM with HbA1c levels of 7.5–10.5% were randomly selected to receive dapagliflozin or placebo treatment for 24 weeks. …”
Get full text

A Systematic Review and Network Meta-Analysis on the Efficacy of Medications in the Treatment of Chronic Idiopathic Constipation in Japan by Atsushi Nakajima, Ayako Shoji, Kinya Kokubo, Ataru Igarashi

“…The results of direct comparisons showed that linaclotide, elobixibat, and lubiprostone were superior to placebo in the change of spontaneous bowel movements (SBMs) within 1 week: linaclotide, 1.95 (95% CI, 1.51-2.39); elobixibat, 5.69 (95% CI, 3.31-8.07); and lubiprostone, 2.41 (95% CI, 0.82-4.01). …”
Get full text

Anthocyanin-Rich Blackcurrant Supplementation as a Nutraceutical Ergogenic Aid for Exercise Performance and Recovery: A Narrative Review by Mark ET Willems, Sam D Blacker, Stefano Montanari, Matthew D Cook

“…This review included 17 studies with a randomized placebo-controlled crossover design (10 studies on performance and 8 on recovery effects) and 1 with a randomized placebo-controlled parallel group design (recovery effects). …”
Get full text

Effects of a Multispecies Probiotic Mixture on Glycemic Control and Inflammatory Status in Women with Gestational Diabetes: A Randomized Controlled Clinical Trial by Sadegh Jafarnejad, Sadaf Saremi, Farzan Jafarnejad, Arman Arab

“…After 8 wk of supplementation FPG, HbA1c, HOMA-IR, and insulin levels remained unchanged in the probiotic and placebo groups. The comparison between the two groups showed no significant differences with FPG and HbA1c, but there were significant differences in insulin levels and HOMA-IR (16.6±5.9; 3.7±1.5, resp.). …”
Get full text

Traditional Chinese Medicine Improves Activities of Daily Living in Parkinson's Disease by Weidong Pan, Shin Kwak, Yun Liu, Yan Sun, Zhenglong Fang, Baofeng Qin, Yoshiharu Yamamoto

“…Patients took either ZAZ2 (𝑛=59) or placebo granule (𝑛=56) in a blind manner for 13 weeks while maintaining other anti-Parkinson medications unchanged. …”
Get full text

Metformin Exhibits Anti‐Inflammatory Effects by Regulating microRNA‐451/CXCL16 and B Cell Leukemia/Lymphoma 2 in Patients With Osteoarthritis by Nahid Alimoradi, Amin Ramezani, Mohammad Tahami, Negar Firouzabadi

“…Methods In this double‐blind placebo‐controlled clinical trial, patients were randomly divided into two groups: one receiving metformin and the other receiving a placebo for four months (starting at 0.5 g/day for the first week, increasing to 1 g/day for the second week, and increasing to 1.5 g/day for the remaining period). …”
Get full text

A New Hope for the Patients of Non‐Alcoholic Steatohepatitis: FDA Gives Green Signal for Resmetirom Use by Abdul Haseeb Hasan, Muhammad Ali Abid, Muhammad Hafi Abid, Laiba Suhail, Abubakar Nazir

“…In a randomized Phase 3 trial, significant histological improvements were observed in 25.9% and 29.9% of patients receiving 80 and 100 mg doses, respectively, compared to 9.7% in the placebo group. Similar trends were noted in fibrosis improvement, with 24.2% and 25.9% of patients showing ≥ 1 stage improvement compared to 14.2% in the placebo group. …”
Get full text

Histological and Immunohistochemical Evaluation of Autologous Cultured Bone Marrow Mesenchymal Stem Cells and Bone Marrow Mononucleated Cells in Collagenase-Induced Tendinitis of E... by Antonio Crovace, Luca Lacitignola, Giacomo Rossi, Edda Francioso

“…The aim of this study was to compare treatment with cultured bone marrow stromal cells (cBMSCs), bone marrow Mononucleated Cells (BMMNCs), and placebo to repair collagenase-induced tendinitis in horses. …”
Get full text

Effects of dipeptidyl peptidase 4 inhibitors on the risk of acute respiratory failure in patients with type 2 diabetes mellitus: a meta-analysis of cardiovascular outcomes trials by Yan Wang, Caiyuan Yu, Xiaoyan Zheng, Yaya Wang, Wei Zhang

“…Overall, there were a nonsignificant increase in the risk of ARF in the DDP-4 inhibitor group compared with the placebo group (RR, 1.72; 95% CI, 0.59 to 4.97; p = 0.319). …”
Get full text

Vitamin D Supplementation Ameliorates Metabolic Dysfunction in Patients with PCOS: A SystematicReview of RCTs and Insight into the Underlying Mechanism by Shan Guo, Reshef Tal, Haoyu Jiang, Tao Yuan, Ying Liu

“…Serum FPG, fasting insulin, HOMA-IR, and VLDL-C were significantly decreased in the vitamin D group versus placebo. Vitamin D supplementation group also showed a significantly elevated level of QUICKI. …”
Get full text

Assessment of Acute and Chronic Pharmacological Effects on Energy Expenditure and Macronutrient Oxidation in Humans: Responses to Ephedrine by Antonella Napolitano, Peter R. Murgatroyd, Nick Finer, Elizabeth K. Hussey, Robert Dobbins, Steve O'Rahilly, Derek J. R. Nunez

“…Volunteers randomly given ephedrine hydrochloride 15 mg QID (n=8) or placebo (n=6) were studied at baseline and after 1-2 and 14-15 days of treatment. …”
Get full text

Low-Level Laser Therapy for Temporomandibular Disorders: A Systematic Review with Meta-Analysis by Gang-Zhu Xu, Jie Jia, Lin Jin, Jia-Heng Li, Zhan-Yue Wang, Dong-Yuan Cao

“…We systematically reviewed randomized controlled trials (RCTs) of the effect of low-level laser therapy (LLLT) versus placebo in patients with temporomandibular disorder (TMD). …”
Get full text

Beneficial Effects of Probiotic Treatment on Gut Microbiota in Very Low Birth Weight Infants by Yue-feng Li, Chuan-rui Zhu, Xue-lei Gong, Hui-ling Li, Li-kuan Xiong, Ke-jian Wang, Guo-Sheng Liu

“…We found that probiotic treatment, but not placebo, decreased the α-diversity of gut microbiota in VLBW infants. …”
Get full text

Zoledronic acid as adjuvant therapy in neovascular age-related macular degeneration: a randomised controlled pilot study by Øystein Kalsnes Jørstad, Morten Carstens Moe, Morten Wang Fagerland, Yngvil Solheim Husum, Erik Fink Eriksen

“…Aims To assess the feasibility of a study protocol for a randomised controlled trial of zoledronic acid (ZA) as adjuvant therapy for neovascular age-related macular degeneration (nAMD).Methods In this 1-year, randomised, double-blinded, placebo-controlled pilot study, nAMD patients were allocated 1:1 to receive intravenous ZA 5 mg or placebo at baseline and after 6 months in addition to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy following a treat-and-extend regimen. …”
Get full text

A Pilot Trial of Pioglitazone HCl and Tretinoin in ALS: Cerebrospinal Fluid Biomarkers to Monitor Drug Efficacy and Predict Rate of Disease Progression by Todd D. Levine, Robert Bowser, Nicole C. Hank, Stephen Gately, Dietrich Stephan, David S. Saperstein, Kendall Van Keuren-Jensen

“…Subjects treated with tretinoin, pioglitazone, and riluzole had an average rate of decline on the ALSFRS-R scale of −1.02 points per month; subjects treated with placebo and riluzole had a rate of decline of -.86 (P=.18). …”
Get full text

Sexual Absorption of Vaginal Progesterone: A Randomized Control Trial by Kathryn S. Merriam, Kristina A. Leake, Mollie Elliot, Michelle L. Matthews, Rebecca S. Usadi, Bradley S. Hurst

“…Prospective, randomized, cross over, controlled study of 20 reproductive-aged women and their male sexual partners randomized to receive vaginal progesterone gel (Crinone 8% gel, Actavis Inc., USA) or placebo cream. Serum progesterone for both male and female partners were measured 10 hours after intercourse. …”
Get full text

Rasagiline as Adjunct to Levodopa for Treatment of Parkinson’s Disease: A Systematic Review and Meta-Analysis by Osamu Kano, Hiroshi Tsuda, Ayako Hayashi, Masaki Arai

“…A systematic literature search was conducted (January 18-19, 2021) using PubMed, Cochrane Library, EMBASE, Web of Science, and Google Scholar to identify randomized controlled trials comparing rasagiline/levodopa versus placebo/levodopa in patients with Parkinson’s disease experiencing motor fluctuations. …”
Get full text